Here is a breakdown of major shareholders in Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI)

Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is 43.55% higher on its value in year-to-date trading and has touched a low of $0.13 and a high of $3.46 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCLI stock was last observed hovering at around $0.38 in the last trading session, with the day’s gains setting it 0.01%.

Currently trading at $0.39, the stock is 15.63% and 37.37% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing 2.06% at the moment leaves the stock -68.73% off its SMA200. BCLI registered -83.03% loss for a year compared to 6-month loss of -75.35%. The firm has a 200-day simple moving average (SMA200) of -$0.97.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 19.05% gain in the last 1 month and extending the period to 3 months gives it a 130.53%, and is 1.79% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.50% over the week and 13.35% over the month.

Brainstorm Cell Therapeutics, Inc. (BCLI) has around 43 employees, a market worth around $19.20M and $0.00M in sales. Distance from 52-week low is 192.46% and -88.67% from its 52-week high.

Brainstorm Cell Therapeutics, Inc. quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 18.18% this year

61 institutions hold shares in Brainstorm Cell Therapeutics, Inc. (BCLI), with institutional investors hold 12.29% of the company’s shares. The shares outstanding are 48.98M, and float is at 40.35M with Short Float at 5.91%. Institutions hold 10.12% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 1.42 million shares valued at $2.93 million. The investor’s holdings represent 3.16% of the BCLI Shares outstanding. As of Jun 29, 2023, the second largest holder is Sabby Management, LLC with 1.27 million shares valued at $2.61 million to account for 2.82% of the shares outstanding. The other top investors are AIGH Capital Management LLC which holds 0.71 million shares representing 1.57% and valued at over $1.46 million, while Susquehanna International Group, LLP holds 1.12% of the shares totaling 0.51 million with a market value of $1.04 million.

Brainstorm Cell Therapeutics, Inc. (BCLI) Insider Activity

A total of 1 insider transactions have happened at Brainstorm Cell Therapeutics, Inc. (BCLI) in the last six months, with sales accounting for 0 and purchases happening 1 times. The most recent transaction is an insider purchase by Lindborg Stacy, the company’s Co-Chief Executive Officer. SEC filings show that Lindborg Stacy bought 11,500 shares of the company’s common stock on Sep 01 at a price of $1.77 per share for a total of $20402.0. Following the purchase, the insider now owns 0.18 million shares.

Brainstorm Cell Therapeutics, Inc. (BCLI): Who are the competitors?

One of the company’s main competitors (and peers) include Biogen Inc. (BIIB) that is trading -16.07% down over the past 12 months.Agenus Inc. (AGEN) lies in the list of competitors of the Brainstorm Cell Therapeutics, Inc. and is -67.99% lower over the same period from BCLICytokinetics Inc. (CYTK) is 81.14% up on the 1-year trading charts.